Certolizumab pegol 200 mg/ML
RxNorm 795079

Concept Hierarchy & Relationship Mapping

RxNorm Concept Unique Identifier (RxCUI) 795079 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: certolizumab pegol 200 mg/ML.

The following semantic concepts and normalized strings are associated with this clinical entity:

SCDC
Certolizumab pegol 200 mg/ML
AUI:2803291

This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.

SCDCPrescribable

Semantic Clinical Drug Component (SCDC):
Certolizumab pegol 200 mg/ML
(Atom ID: 2803291)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
certolizumab pegol 200 MG/ML
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
795079
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
2803291
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SCDC
Semantic Clinical Drug Component (Ingredient + Strength)
Source Code
795079
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Technical Attributes & Logic

RXN BOSS STRENGTH DENOM UNIT
ML
RXN Boss Strength Denom Unit
RXN BOSS STRENGTH DENOM VALUE
1
RXN Boss Strength Denom Value
RXN BOSS STRENGTH NUM UNIT
MG
RXN Boss Strength Num Unit
RXN BOSS STRENGTH NUM VALUE
200
RXN Boss Strength Num Value
RXN STRENGTH
200 MG/ML
Strength plus unit of SCDC

Patient Education

Certolizumab Injection


Certolizumab injection is used to relieve the symptoms of certain autoimmune disorders (conditions in which the immune system attacks healthy parts of the body and causes pain, swelling, and damage) including the following: Crohn's disease (a condition in which the body attacks the lining of the digestive tract, causing pain, diarrhea, weight loss, and fever) that has not improved when treated with other medications, rheumatoid arthritis (a condition in which the body attacks its own joints, causing pain, swelling, and loss of function), psoriatic arthritis (a condition that causes joint pain and swelling and scales on the skin), active ankylosing spondylitis (a condition in which the body attacks the joints of the spine and other areas causing pain, swelling, and joint damage) with changes seen on X-ray, active non-radiographic axial spondyloarthritis (a condition in which the body attacks the joints of the spine and other areas causing pain and signs of swelling), but without changes seen on X-ray, plaque psoriasis (a skin disease in which red, scaly patches form on some areas of the body) in people who may benefit from medications or phototherapy (a treatment that involves exposing the skin to ultraviolet light). Certolizumab injection is in a class of medications called tumor necrosis factor (TNF) inhibitors. It works by blocking the activity of TNF, a substance in the body that causes inflammation.
[Learn More]


* Please review the disclaimer below.